Cytochrome P450-derived eicosanoids: the neglected pathway in cancer

Endogenously produced lipid autacoids are locally acting small molecule mediators that play a central role in the regulation of inflammation and tissue homeostasis. A well-studied group of autacoids are the products of arachidonic acid metabolism, among which the prostaglandins and leukotrienes are the best known. They are generated by two pathways controlled by the enzyme systems cyclooxygenase and lipoxygenase, respectively. However, arachidonic acid is also substrate for a third enzymatic pathway, the cytochrome P450 (CYP) system. This third eicosanoid pathway consists of two main branches: ω-hydroxylases convert arachidonic acid to hydroxyeicosatetraenoic acids (HETEs) and epoxygenases convert it to epoxyeicosatrienoic acids (EETs). This third CYP pathway was originally studied in conjunction with inflammatory and cardiovascular disease. Arachidonic acid and its metabolites have recently stimulated great interest in cancer biology; but, unlike prostaglandins and leukotrienes the link between cytochome P450 metabolites and cancer has received little attention. In this review, the emerging role in cancer of cytochrome P450 metabolites, notably 20-HETE and EETs, are discussed

Supplementary Table 1 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes

Association between fibroids diagnosed before age 35 (+/- uterine surgery) and breast cancer incidence, stratified by menopause status, using Cox proportional hazards models</p

Supplemental Figure 1 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes

Histogram demonstrating the distribution of the age of diagnosis of both endometriosis and fibroids in the Sister Study cohort.</p

Supplementary Table 4 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes

Association between fibroids and hormone receptor status among only Black / African American breast cancer cases</p

Supplementary Table 2 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes

Association between endometriosis diagnosed before age 35 (+/- uterine surgery) and breast cancer overall and stratified by menopause status using Cox proportional hazards model</p

Supplementary Table 5 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes

Association between fibroids and hormone receptor status among only Non- Black / African American breast cancer cases</p

Supplemental Figure 2 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes

Results from logistic regression model among breast cancer cases assessing the relationship between history of fibroids or endometriosis and breast cancer subtype (ER+ versus ER-, PR+ versus PR-, HER2+ versus HER2- and triple-negative vs. non-triple-negative), stratified by race. The referent group is no fibroids (or no endometriosis), regardless of surgical history. Age adjusted, partially adjusted, and fully adjusted models are included.</p

Supplementary Table 6 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes

Association between fibroids and triple negative subtype among cases, stratified by race/ethnicity using logistic regression models</p

Supplementary Table 3 from Association of Fibroids, Endometriosis, and Gynecologic Surgeries with Breast Cancer Incidence and Hormone Receptor Subtypes

Association between fibroids or endometriosis (+\- surgical status) and hormone receptor subtype among breast cancer cases using logistic regression models</p